Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.
The Natural History and Neuroprotection in Parkinson Plus Syndromes (NNIPPS) study was a large phase III randomized placebo-controlled trial of riluzole in Progressive Supranuclear Palsy (PSP, n = 362) and Multiple System Atrophy (MSA, n = 398). To assess disease severity and progression, we constru...
Main Authors: | Christine A M Payan, François Viallet, Bernhard G Landwehrmeyer, Anne-Marie Bonnet, Michel Borg, Franck Durif, Lucette Lacomblez, Frédéric Bloch, Marc Verny, Jacques Fermanian, Yves Agid, Albert C Ludolph, Peter N Leigh, Gilbert Bensimon, NNIPPS Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3150329?pdf=render |
Similar Items
-
The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom.
by: Paul McCrone, et al.
Published: (2011-01-01) -
Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy
by: Jesse A. Brown, et al.
Published: (2017-01-01) -
“Penguin” or “Hummingbird” Sign and Midbrain Atrophy in Progressive Supranuclear Palsy
by: Pelin Nar, et al.
Published: (2010-12-01) -
“Penguin” or “Hummingbird” Sign and Midbrain Atrophy in Progressive Supranuclear Palsy
by: Pelin Nar, et al.
Published: (2010-12-01) -
Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.
by: Akio Mori, et al.
Published: (2019-01-01)